Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder

Abstract

Introduction: Limited information is available on the clinical issues and strategies for optimal clinical usage of ziprasidone in the treatment of adult patients with acute manic or mixed episodes of bipolar disorder.

Areas covered: To address those issues, information from clinical trials addressing the efficacy and tolerability of ziprasidone in acute bipolar mania was reviewed and supplemented with the input from an expert faculty of European psychiatrists with extensive experience in treating patients with bipolar mania, both in clinical trials and in everyday clinical practice.

Expert opinion: Effective use of oral ziprasidone in the treatment of acute bipolar mania requires rapid titration to doses in the range 120 – 160 mg/day and administration with meals of ≥ 500 kcal. As in the clinical trials, temporary short-term use of benzodiazepines (in particular lorazepam for agitation or temazepam for insomnia) could be advisable. Available evidence from randomized clinical trials in combination with clinical experience supports the use of ziprasidone as one of the first-line effective and safe treatments for acute manic or mixed episodes associated with bipolar I disorder.

Keywords:

• agitation
• benzodiazepines
• bipolar disorder
• concomitant
• dosing
• effect of food
• efficacy
• insomnia
• mania
• manic episodes
• mixed episodes
• rapid up-titration
• somnolence
• tolerability
• ziprasidone

Acknowledgements

The authors acknowledge the efforts of M Zivkov in providing editorial support, preparing the first draft of the manuscript, revising the manuscript based on author feedback, and styling the manuscript for journal submission; and of C Hall in preparing the figures and tables.

Notes